Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company focused on next-generation antibody-drug conjugate technology for oncology indications. The company entered public markets through a SPAC merger with Ignyte Acquisition Corp., a blank-check company that completed its initial public offering in 2021 and targeted the healthcare and life-sciences sector. Peak Bio's 10-Q filing, submitted July 26, 2021, represents an early quarterly disclosure as a newly public entity, covering the period following the SPAC transaction's close. The company is developing ADC platforms designed to address solid tumors and hematologic malignancies, operating within a competitive and capital-intensive biotechnology landscape. Investors and analysts looking for Peak Bio's complete filing history, SPAC deal terms, and ongoing company data can sign up for full access at SpacDesk.